^
    17d
    A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Oct 2024
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    cyclophosphamide • CCT303-406
    over2years
    A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=15, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2022 --> Oct 2022
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    cyclophosphamide • CCT303-406
    over4years
    A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=15, Recruiting, Shanghai PerHum Therapeutics Co., Ltd.
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    CCT303-406